/R E P E A T -- VVT Med Receives Order from Major US Healthcare Network NorthWell Health and Enters Into Investor Relations Agreements/

Executive Summary

• VVT Med received an initial order for its ScleroSafe™ varicose vein treatment system from Northwell Health, one of the largest U.S. healthcare networks, marking the company’s first scaled entry into the U.S. public‑hospital market.
• The Company entered into investor‑relations agreements with I3 Capital Group Ltd. and Revolution Small Cap Marketing, including cash fees, a grant of 400,000 stock options to I3, and a CAD $40,000 marketing fee to Revolution.
• Both agreements are subject to TSX Venture Exchange approval and shareholder ratification of the equity incentive plan.

Key Details

• Northwell Health Order – Initial purchase of “several units” of ScleroSafe™ for deployment under Dr. Antonios Gasparis, Director of the Center for Vein Care.
• Strategic Significance – Provides a reference client in the U.S., expected to facilitate broader adoption across Northwell’s 28 hospitals and 1,000+ clinics.
• I3 Capital Group Agreement (dated Oct 28 2025)
• Term: 3 months initial, auto‑renews quarterly unless 30‑day notice given.
• Compensation: Cash $55,000 total (initial $10,000 + HST; $10,000 + HST per month for first three months; thereafter $5,000 + HST per month for next three months, no cash fees for subsequent six months).
• Equity Incentive: Grant of 400,000 stock options under the Company’s equity incentive plan (two‑year term, vesting in four equal tranches of 100,000 options each, beginning three months after grant).
• Revolution Small Cap Marketing Agreement
• Term: 90 days starting Oct 28 2025, renewable by mutual consent.
• Compensation: CAD $40,000 plus applicable taxes; no securities issued as payment.
• Shareholdings & Arm’s‑Length Status – I3 holds/controls ~318,000 common shares (plus rights to acquire 57,590 more) but has no other present interest; Revolution holds no securities. Both parties are arm’s‑length.
• Approvals Required – Both agreements and the stock option grant require TSX Venture Exchange approval and shareholder ratification of the equity incentive plan.

Notable Quotes

“Only 2% of symptomatic varicose vein patients undergo treatment, largely due to the lack of ideal solutions… VVT's ScleroSafe™ enables these treatments to be completed in a more accessible manner, minimizing pain and post‑procedure care,” – Erez Tetro, CEO, VVT Med.